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Development of Inhalable Nano-lipid Carriers for the Treatment of Pulmonary Aspergillosis
using Hot Melt Extrusion Technology

Project Summary
Overview: I am Gauri Shadambikar, second year PhD. student in department of Pharmaceutics
and Drug Delivery. Pulmonary Aspergillosis is an infection caused by a type of mold and can
have serious effects on patients with a weak immune system or with underlying lung disease1.
Itraconazole, a triazole is a compound with a broad antifungal spectrum2. An inhalation-based
drug delivery system has the advantage of rapid onset of action directly at the site of infection
along with controlled and prolonged delivery3. Hence the aim of my project was to prepare
inhalable nano-lipid carriers (NLC) which would be a viable and efficient alternative to
traditional routes such as oral administration.
Intellectual Merit: Pulmonary Aspergillosis, is a mycotic disease caused by Aspergillus
fumigatus, a saprophytic and ubiquitous airborne fungus. Fungal infections such as
Aspergillosis can be life threatening for immunocompromised patients4. The lung as a major
port of entry into the body and site of infection plays an important role in this disease.
Itraconazole, a broad-spectrum antifungal compound helps in inhibiting the fungal cell
membrane5. The treatment for pulmonary aspergillosis includes several weeks of
administration of antifungal medicines given orally. The above-mentioned delivery mode for
treatment depends on systemic absorption resulting in undesirable side effects of itraconazole
such as nausea, abdominal pain and hepatotoxicity. To overcome aforementioned issues, there
is a need to have products that are able to achieve an instant therapeutic level and able to
maintain its level in the body for longer periods of time. Inhalation drug delivery represents a
potential delivery route for the treatment of pulmonary diseases. It has several advantages as
it can directly reach the lung epithelium resulting in faster onset of action 6. Also, the dosing
and dose can be reduced compared to the traditional oral route as it can avoid first pass
metabolism and systemic toxicity. Biodegradable nano-lipid carriers (NLC) of lipophilic
compounds have the potential advantage in protecting the compound from degradation and
releasing the drug in a controlled manner for a prolonged period. These NLCs can be
immediately released into the pulmonary epithelium by nebulization and control the release of
itraconazole for prolonged periods. Utilizing hot melt extrusion technology for preparation of
nanoparticles over the conventional method will be energy efficient, as well as environmentally
and industry friendly7.
External Opportunity: We will use the preliminary data to write a pre-doctoral grant proposal
to FDA, Broad Agency Announcement of 2020 (FDABAA-20-00123). New delivery systems
for mycotic diseases is applicable to this announcement. The potential funding amount, in a
collaboration could be $250K/year which is due in April of 2020. This accomplishment would
propel my academic career and will provide a promising job offer.
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